Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARγ

Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARγ

Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease that lacks effective treatment modalities. Once patients are diagnosed with IPF, their median survival is approximately 3–5 years. PPARγ is an important target for the prevention and treatment of pulmonar...

Full description

Bibliographic Details
Main Authors: Qian Zeng, Ting-ting Zhou, Wen-jie Huang, Xiao-ting Huang, Lei Huang, Xiao-hua Zhang, Xiao-xue Sang, Yu-yang Luo, Yu-mei Tian, Bin Wu, Lin Liu, Zi-qiang Luo, Bin He, Wei Liu, Si-yuan Tang
Format: Article
Language:English
Published: Nature Portfolio 2023-09-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-41933-5

Internet

https://doi.org/10.1038/s41598-023-41933-5

Similar Items